Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Integrative multi-omics analysis and machine learning identify M2 macrophage-induced ferroptosis resistance in glioblastoma.

Functional & integrative genomics·2026
Same author

Morphology spectrum and molecular landscape in eosinophilic solid and cystic renal cell carcinoma.

Human pathology·2026
Same author

Incidental Finding of Secondary Focal Segmental Glomerulosclerosis in Renal Allograft due to Renal Artery Stenosis.

Pediatric transplantation·2026
Same author

The global hydrogen budget.

Nature·2025
Same author

TRIM67 Suppresses Glioblastoma Glycolysis and Increases Temozolomide Sensitivity by Promoting ARSD Ubiquitinated Degradation to Inactivate the β-Catenin Pathway.

FASEB journal : official publication of the Federation of American Societies for Experimental Biology·2025
Same author

A Novel Perspective on Tubular C4d Positivity in BK Polyomavirus Nephropathy.

Kidney international reports·2025
Same journal

Natural killer cell-derived extracellular vesicles reprogram cellular human immunity to enhance tumor cytotoxicity.

Molecular therapy. Oncology·2026
Same journal

PARP7 inhibitors enhance the immunogenic effects of radiation in pancreatic cancer cells.

Molecular therapy. Oncology·2026
Same journal

Patient-derived tumor organoids for personalized cancer immunotherapy: An immunopeptidome-to-validation approach in RCC and BC.

Molecular therapy. Oncology·2026
Same journal

Development of chimeric antigen receptors targeting the γδ T cell receptor.

Molecular therapy. Oncology·2026
Same journal

Tumoricidal efficacy of DZ-1 dye conjugated to dihydroartemisinin in patient-derived colorectal liver metastasis tumoroids.

Molecular therapy. Oncology·2026
Same journal

mRNA vaccination using peptide nanoparticles triggers a strong immune response against endogenous GPC2 in a murine neuroblastoma model.

Molecular therapy. Oncology·2026
See all related articles

Related Experiment Video

Updated: Jun 18, 2025

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K

Comprehensive machine learning-based integration develops a novel prognostic model for glioblastoma.

Qian Jiang1, Xiawei Yang2, Teng Deng1

  • 1Department of Neurosurgery, Guangxi Medical University Cancer Hospital, Nanning, Guangxi, China.

Molecular Therapy. Oncology
|July 29, 2024
PubMed
Summary
This summary is machine-generated.

This study introduces a new artificial intelligence prognostic signature (AIPS) for glioblastoma (GBM) that accurately predicts patient outcomes and guides treatment strategies.

Keywords:
Glioblastomaimmunotherapy.machine learningprognostic signaturetumor immune microenvironment

More Related Videos

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

1.5K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K

Related Experiment Videos

Last Updated: Jun 18, 2025

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma
04:09

Predicting Treatment Response to Image-Guided Therapies Using Machine Learning: An Example for Trans-Arterial Treatment of Hepatocellular Carcinoma

Published on: October 10, 2018

8.2K
Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations
04:46

Glioblastoma Relapse Post-Resection Model for Therapeutic Hydrogel Investigations

Published on: February 24, 2023

1.5K
Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures
06:32

Evaluation of Biomarkers in Glioma by Immunohistochemistry on Paraffin-Embedded 3D Glioma Neurosphere Cultures

Published on: January 9, 2019

7.8K

Area of Science:

  • Oncology
  • Bioinformatics
  • Artificial Intelligence

Background:

  • Glioblastoma (GBM) remains a challenging brain tumor with limited effective prognostic models.
  • Accurate prediction of GBM patient prognosis is crucial for developing personalized treatment strategies.

Purpose of the Study:

  • To develop and validate a novel, integrated machine learning-based prognostic model for glioblastoma.
  • To compare the performance of the new model against existing prognostic tools.
  • To investigate the relationship between the new prognostic signature and the tumor immune microenvironment (TIME) and immunotherapy response.

Main Methods:

  • Univariate Cox regression analysis was employed to identify prognostic genes across six GBM cohorts.
  • An artificial intelligence prognostic signature (AIPS) was developed by integrating 10 machine learning algorithms into 117 combinations.
  • The AIPS performance was evaluated using the C-index and compared with 10 previously published models.

Main Results:

  • The AIPS, utilizing the random survival forest algorithm, achieved the highest average C-index (0.868), outperforming existing models.
  • The AIPS demonstrated a strong correlation with GBM clinical features.
  • Lower AIPS scores were associated with improved prognosis, a more active TIME, and enhanced immunotherapy sensitivity.

Conclusions:

  • The developed AIPS serves as an effective prognostic tool for glioblastoma.
  • This signature offers valuable insights for stratifying GBM patients and optimizing treatment approaches.
  • Further validation of key gene expression through western blotting and immunohistochemistry supports the AIPS findings.